Neos Therapeutics Inc (NASDAQ:NEOS) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded Neos Therapeutics Inc (NASDAQ:NEOS) to Sell in a statement released on Wednesday October 12, 2016.
Having a price of $6.88, Neos Therapeutics Inc (NASDAQ:NEOS) traded -0.43% lower on the day. With the last stock price down -20.75% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. NEOS has recorded a 50-day average of $7.07 and a two hundred day average of $8.68. Trade Volume was down over the average, with 111,604 shares of NEOS changing hands under the typical 136,820
Recent Performance Chart
Neos Therapeutics Inc has with a one year low of $6.33 and a one year high of $19.29 and has a market capitalization of $0.
A total of 4 brokerages have released a report on Neos Therapeutics Inc. 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $22.50.
Brief Synopsis On Neos Therapeutics Inc (NASDAQ:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.